This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sangamo Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Upon executing the agreement, we announced the selection of hemophilia targets Factors VII, VIII, IX and X. Shire also received an option to name three additional targets. I'm very pleased to announce today that Shire has selected a fifth target and has committed to support the development of the ZFP Therapeutics for Huntington’s disease. A program that we had previously initiated with funding from the CHDI Foundation, a research foundation focused on developing a cure for Huntington’s disease. I have asked Philip to provide you with some background on the disease and more details on why we believe our technology can generate the unique approach for the treatment of Huntington’s later on the call.

Because our ZFP technology works very specifically and efficiently at the DNA level, it enables us to provide unique therapeutic solutions to diseases where the cause has been traced to a defect in a single gene so-called monogenic diseases. Huntington’s is a well studied example as you will hear later.

However, there are many monogenic diseases. We are actively working on several other single gene based disorders some of which were highlighted in presentations at the Annual American Society for Gene & Cell Therapy Meeting in June. However, up to this point, beyond presentations of data at scientific meetings and publications and peer-reviewed journals. We have not provided a great deal of visibility on these programs that will change at the end of this year.

We planned to host an Analyst Briefing on December 6, at which time, we will discuss our preclinical monogenic diseases programs, our development plans, and the timing for IND filings, and associated financial projections. The briefing will be brought, it will be webcast and details regarding the exact timing of the event will follow later this year.

Moving on to our lead clinical program, SB-728, which we are developing as a potential functional cure for HIV, I’m pleased to report that our two Phase II studies are also progressing on plan. As most of you know based upon encouraging Phase I data, we announced the initiation of two Phase II trials during the first quarter of this year. At that time we said that we would update you on the expected timing of clinical data once we have had an opportunity to asses the rate of enrollment.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs